Phase I/II study of Resiquimod as an immunologic adjuvant for NY-ESO-1 protein vaccination in patients with melanoma. (7th November 2013) - Sabado, Rachel L; Pavlick, Anna; Gnjatic, Sacha; Cruz, Crystal; Vengco, Isabelita; Hasan, Farah; Darvishian, Farbod; Chiriboga, Luis; Holman, Rose Marie; Escalon, Juliet; Muren, Caroline; Escano, Crystal; et al.